Can Type 1 Diabetes Be Prevented? Screening and Risk Assessment in Clinical Trials: A Narrative Review.
DOI:
https://doi.org/10.12775/QS.2026.56.72439Keywords
type 1 diabetes, screening, risk assessment, preclinical stage, preventionAbstract
Background. This review summarises recent clinical trials on type 1 diabetes (T1D) and emerging screening and prevention strategies. The increasing incidence of T1D raises interest in early detection and potential prevention. Ongoing studies focus on newborn risk assessment, islet autoantibody screening and preventive strategies.
Aim. This review aims to present current knowledge on T1D prevention, screening methods for risk assessment and identification of preclinical disease, and to highlight recent directions in clinical research.
Material and methods. A literature search was conducted in PubMed, Scopus and Google Scholar. Retrospective and cohort studies, literature reviews, systematic reviews, guidelines, clinical trial protocols and randomised controlled trials were included. The following keywords were used: ‘type 1 diabetes’, ‘risk factors’, ‘ketoacidosis’, ‘screening’, ‘newborn screening’, ‘genetic risk’, ‘prevention’, ‘preclinical stage’. The search focused on recent clinical trials.
Results. Clinical studies demonstrate a shift towards earlier detection of T1D through screening strategies combining genetic risk assessment with islet autoantibody testing. These strategies allow identification of at-risk individuals and long-term monitoring. Studies confirm that detection of preclinical stages is associated with reduced incidence of diabetic ketoacidosis at diagnosis and a milder disease course. Early diagnosis enables access to disease-modifying therapy with teplizumab, which can delay disease progression. Preventive approaches, including oral insulin immunotherapy and microbiome-targeted interventions, are under investigation, with mixed results.
Conclusions. T1D can be identified at earlier stages using combined genetic and immunological screening strategies, improving clinical outcomes at diagnosis. However, effective prevention remains limited. Further research is required to optimise screening and its implementation in clinical practice.
References
1. Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, et al. Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care. 2018 Sep 1;41(9):2026–44. doi:10.2337/DCI18-0023 PubMed PMID: 30093549.
2. Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ. Improvements in the Life Expectancy of Type 1 DiabetesThe Pittsburgh Epidemiology of Diabetes Complications Study Cohort. Diabetes. 2012 Nov 1;61(11):2987–92. doi:10.2337/DB11-1625 PubMed PMID: 22851572.
3. Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. The Lancet. 2020 Dec 19;396(10267):2019–82. doi:10.1016/S0140-6736(20)32374-6/ASSET/5FF393CC-06D4-4BDA-9BDF-BDEB60045960/MAIN.ASSETS/GR3.JPG PubMed PMID: 33189186.
4. Ou HT, Yang CY, Wang J Der, Hwang JS, Wu JS. Life Expectancy and Lifetime Health Care Expenditures for Type 1 Diabetes: A Nationwide Longitudinal Cohort of Incident Cases Followed for 14 Years. Value in Health. 2016 Dec 1;19(8):976–84. doi:10.1016/j.jval.2016.05.017 PubMed PMID: 27987648.
5. Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, et al. Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. JAMA. 2015 Jan 6;313(1):37. doi:10.1001/JAMA.2014.16425 PubMed PMID: 25562264.
6. Ogle GD, Wang F, Haynes A, Gregory GA, King TW, Deng K, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res Clin Pract. 2025 Jul 1;225:112277. doi:10.1016/J.DIABRES.2025.112277 PubMed PMID: 40412624.
7. Gregory GA, Robinson TIG, Linklater SE, Wang F, Colagiuri S, De Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10:741–60. doi:10.1016/S2213-8587(22)00218-2
8. Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for Islet Autoimmunity among Monozygotic Twins. New England Journal of Medicine. 2008 Dec 25;359(26):2849–50. doi:10.1056/NEJMC0805398/ASSET/BC6A1F8E-D5D7-4916-9A0B-F0BEE208B704/ASSETS/IMAGES/LARGE/NEJMC0805398_F1.JPG PubMed PMID: 19109586.
9. Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. The Lancet. 2016 Jun 4;387(10035):2331–9. doi:10.1016/S0140-6736(16)30582-7/ASSET/ACB8F4B3-EFCB-4DF6-9442-9962635190C5/MAIN.ASSETS/GR5.SML PubMed PMID: 27302272.
10. Hagopian WA, Sharp SA, Rich SS, Wood AR, Jones SE, Beaumont RN, et al. Development and Standardization of an Improved Type 1 Diabetes Genetic Risk Score for Use in Newborn Screening and Incident Diagnosis. Diabetes Care. 2019;42. doi:10.2337/dc18-1785
11. Hommel A, Haupt F, Delivani P, Winkler C, Stopsack M, Wimberger P, et al. Screening for Type 1 Diabetes Risk in Newborns: The Freder1k Pilot Study in Saxony. Horm Metab Res. 2018 Jan 1;50(1):44–9. doi:10.1055/S-0043-120921 PubMed PMID: 29121687.
12. Bonifacio E, Achenbach P. Birth and coming of age of islet autoantibodies. Clin Exp Immunol. 2019 Dec 1;198(3):294–305. doi:10.1111/CEI.13360 PubMed PMID: 31397889.
13. Besser REJ, Bell KJ, Couper JJ, Ziegler AG, Wherrett DK, Knip M, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2022 Dec 1;23(8):1175–87. doi:10.1111/PEDI.13410 PubMed PMID: 36177823.
14. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022 Jan 1;45:S17–38. doi:10.2337/DC22-S002 PubMed PMID: 34964875.
15. Cherubini V, Grimsmann JM, Åkesson K, Birkebæk NH, Cinek O, Dovč K, et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia. 2020 Aug 1;63(8):1530–41. doi:10.1007/S00125-020-05152-1 PubMed PMID: 32382815.
16. Raab J, Haupt F, Scholz M, Matzke C, Warncke K, Lange K, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6(5):e011144. doi:10.1136/BMJOPEN-2016-011144 PubMed PMID: 27194320.
17. Schneider J, Gemulla G, Kiess W, Berner R, Hommel A. Presymptomatic type 1 diabetes and disease severity at onset. Diabetologia. 2023 Dec 1;66(12):2387. doi:10.1007/S00125-023-05999-0 PubMed PMID: 37750892.
18. Hummel S, Friedl N, Winkler C, Ziegler AG, Achenbach P. Presymptomatic type 1 diabetes and disease severity at onset. Reply to Schneider J, Gemulla G, Kiess W et al [letter]. Diabetologia. 2023 Dec 1;66(12):2389. doi:10.1007/S00125-023-06017-Z PubMed PMID: 37723346.
19. Hummel S, Carl J, Friedl N, Winkler C, Kick K, Stock J, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia. 2023 Sep 1;66(9):1633. doi:10.1007/S00125-023-05953-0 PubMed PMID: 37329450.
20. Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, et al. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. 2018 Apr 1;62(4):655. doi:10.1007/S00125-018-4786-9 PubMed PMID: 30569273.
21. Hoffmann L, Kohls M, Arnolds S, Achenbach P, Bergholdt R, Bonifacio E, et al. EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents. BMJ Open. 2025;15:88522. doi:10.1136/bmjopen-2024-088522
22. Moran TP, Vickery BP, Burks AW. Oral and sublingual immunotherapy for food allergy: current progress and future directions. Curr Opin Immunol. 2013 Dec;25(6):781. doi:10.1016/J.COI.2013.07.011 PubMed PMID: 23972904.
23. Ziegler AG, Bonifacio E. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012 Jul;55(7):1937–43. doi:10.1007/S00125-012-2472-X PubMed PMID: 22289814.
24. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. Journal of Clinical Investigation. 2004 Aug 16;114(4):589. doi:10.1172/JCI21307 PubMed PMID: 15314696.
25. Ziegler AG, Achenbach P, Weiß A, Berner R, Casteels K, Elding Larsson H, et al. Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial. The Lancet. 2025 Nov 29;406(10519):2564–76. doi:10.1016/S0140-6736(25)01726-X PubMed PMID: 41237794.
26. Ziegler AG, Arnolds S, Kölln A, Achenbach P, Berner R, Bonifacio E, et al. Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. doi:10.1136/bmjopen-2021-052449
27. Winkler C, Haupt F, Heigermoser M, Zapardiel-Gonzalo J, Ohli J, Faure T, et al. Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results. Pediatr Diabetes. 2019;20(6):720. doi:10.1111/PEDI.12870 PubMed PMID: 31192505.
28. Uusitalo U, Liu X, Yang J, Aronsson CA, Hummel S, Butterworth M, et al. Association of Early Exposure of Probiotics and Islet Autoimmunity in the TEDDY Study. JAMA Pediatr. 2016 Jan 1;170(1):20–8. doi:10.1001/JAMAPEDIATRICS.2015.2757 PubMed PMID: 26552054.
29. Endesfelder D, Castell WZ, Ardissone A, Davis-Richardson AG, Achenbach P, Hagen M, et al. Compromised gut microbiota networks in children with anti-islet cell autoimmunity. Diabetes. 2014;63(6):2006–14. doi:10.2337/DB13-1676 PubMed PMID: 24608442.
30. Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. 2018 Oct 25;562(7728):589–94. doi:10.1038/S41586-018-0620-2 PubMed PMID: 30356183.
31. Rubio García A, Paterou A, Lee M, Sławí nski H, Wicker LS, Todd JA, et al. Peripheral tolerance to insulin is encoded by mimicry in the microbiome [Internet]. doi:10.1101/2019.12.18.881433
32. Hsiao KC, Ponsonby AL, Axelrad C, Pitkin S, Tang MLK, Burks W, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health. 2017 Oct 1;1(2):97–105. doi:10.1016/S2352-4642(17)30041-X PubMed PMID: 30169215.
33. Mariño E, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J, et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat Immunol. 2017 Apr 18;18(5):552–62. doi:10.1038/NI.3713 PubMed PMID: 28346408.
34. Stewart CJ, Ajami NJ, O’Brien JL, Hutchinson DS, Smith DP, Wong MC, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature. 2018 Oct 25;562(7728):583–8. doi:10.1038/S41586-018-0617-X PubMed PMID: 30356187.
35. Sommer F, Bäckhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol. 2013 Apr;11(4):227–38. doi:10.1038/NRMICRO2974 PubMed PMID: 23435359.
36. Vatanen T, Kostic AD, D’Hennezel E, Siljander H, Franzosa EA, Yassour M, et al. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell. 2016 May 5;165(4):842–53. doi:10.1016/J.CELL.2016.04.007 PubMed PMID: 27133167.
37. Amenyogbe N, Kollmann TR, Ben-Othman R. Early-life host-microbiome interphase: The key frontier for immune development. Front Pediatr. 2017 May 24;5. doi:10.3389/FPED.2017.00111
38. Davis-Richardson AG, Ardissone AN, Dias R, Simell V, Leonard MT, Kemppainen KM, et al. Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. Front Microbiol. 2014;5(DEC). doi:10.3389/FMICB.2014.00678
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Małgorzata Tesla, Anna Agnieszka Gąska, Marta Gutkowska, Joanna Jabłońska, Joanna Wasik, Marta Armuła, Claire Bongage, Arkadiusz Piechowiak, Filip Napieraj, Bartosz Przemysław Herc

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 5
Number of citations: 0